Paris (ots/PRNewswire) – - First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin
Sanofi announced today data presented at the 47th Annual Meeting of the European Association for the Study of Diabetes to show that adding mealtime Apidra(R) (insulin glulisine) to Lantus(R) (insulin glargine) is more efficacious, with less hypoglycemia, than introducing aspart premixed insulin twice daily.
“Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine” [ABSTRACT 3515]
Results from the All-to-Target trial show that people with type 2 diabetes, whose treatment with oral antidiabetic therapy is unsuccessful, may advance to intensified insulin treatment. Adding mealtime Apidra(R) insulin to a Lantus(R) basal-insulin regimen is an effective treatment strategy for insulin intensification, sustaining continuity of care throughout the duration of the disease.
The stepwise addition of Apidra(R) prandial (mealtime) doses to Lantus(R) treatment can also be an effective introduction to a full basal-bolus regimen.
All-to-Target is a 60-week, randomized, open-label study comparing efficacy, hypoglycemia rates and body weight in people with type 2 diabetes treated with three different insulin regimens: premixed 70/30 protamine-aspart/aspart twice daily (n = 192); Lantus(R) plus one prandial dose of Apidra(R) (n = 189); and Lantus(R) plus stepwise addition of Apidra(R) (n = 191).
Significantly more people reached target HbA1c
No Comments on "More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra® on top of Lantus® Than with Twice-daily Aspart Premixed Insulin"